View Financial HealthBLS Pharmaceuticals 配当と自社株買い配当金 基準チェック /06BLS Pharmaceuticals配当金を支払った記録がありません。主要情報n/a配当利回り-1.3%バイバック利回り総株主利回り-1.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026Board Change • Dec 30Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 Australia決済の安定と成長配当データの取得安定した配当: PR80の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: PR80の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場BLS Pharmaceuticals 配当利回り対市場PR80 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (PR80)n/a市場下位25% (DE)1.6%市場トップ25% (DE)4.7%業界平均 (Life Sciences)0.8%アナリスト予想 (PR80) (最長3年)n/a注目すべき配当: PR80は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: PR80は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: PR80の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: PR80が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 22:41終値2026/07/23 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BLS Pharmaceuticals Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 05Bioxyne Limited Announces Appointment of Edward Myer as Independent Non-Executive Director and Independent Chair of Audit and Finance CommitteeBioxyne Limited had appointed Edward Myer as an independent Non-Executive Director of the Company. Mr. Myer was also appointed as the independent chair of the Audit and Finance Committee. The appointment strengthened Bioxyne’s governance, financial markets and strategic investment capability. Edward Myer brought more than a decade of board and governance experience, including involvement with family office investment structures and private company boards. His board experience spanned investment oversight, capital allocation, shareholder alignment and working closely with management teams to support businesses through periods of growth, change and strategic development. The appointment supported the Board across both the Audit and Finance Committee and the Remuneration Committee, including providing independent oversight across these committees. Ed Myer was an experienced investor and business executive with a background across financial markets, private investment, technology and healthcare sectors. Through MWP Partners Ltd, he had been actively involved in identifying, investing in and supporting growth-stage businesses with long-term strategic potential, with a focus on strategic growth, capital allocation and value creation. He had worked extensively with global investment banks across capital markets in London, Hong Kong and Australia. Ed held a Bachelor of Business (marketing) from Monash University, Graduate Diploma of Applied Finance from Macquarie University and was a graduate member of the Australian Institute or Company Directors. The appointment of Mr. Myer would take immediate effect following completion of the required documentation and checks. Mr. Myer would stand for election by shareholders at the Company’s next Annual General Meeting.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Executive Independent Chairman Tony Ho was the last independent director to join the board, commencing their role in 2012. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 13Bioxyne Limited to Report First Half, 2026 Results on Feb 26, 2026Bioxyne Limited announced that they will report first half, 2026 results on Feb 26, 2026
Board Change • Dec 30Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. 1 highly experienced director. 1 independent director (2 non-independent directors). Non-Executive Independent Chairman Tony Ho is the most experienced director on the board, commencing their role in 2012. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Dec 16Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.Bioxyne Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 115,600,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,400,000 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 28Bioxyne Limited, Annual General Meeting, Nov 26, 2025Bioxyne Limited, Annual General Meeting, Nov 26, 2025. Location: at addisons level 9, 2 park street, sydney nsw 2000 Australia